Key result
Early AF catheter ablation provides mortality and symptom benefits in ischemic cardiomyopathy.
This review highlights the pathophysiology, evaluation, and catheter-directed treatment strategies for atrial and ventricular arrhythmias in patients with ischemic cardiomyopathy.
Atrial and ventricular arrhythmias are highly comorbid with ischemic cardiomyopathy (ICM) and are associated with worsening symptoms, morbidity, and mortality. This review will discuss the pathophysiology, evaluation, and treatment of each arrhythmia in ICM with a focus on novel evaluation strategies and catheter-directed interventions. For atrial fibrillation /atrial flutter, recent studies have demonstrated mortality and symptom benefit with early rhythm control with catheter ablation. With respect to ventricular tachycardia, scar characterization is being investigated to change primary prevention and novel ablation technologies and strategies are being explored.
No takes yet. Share an insight, caveat, or question.
Sehgal et al. (2026) conducted a review in Atrial and ventricular arrhythmias in ischemic cardiomyopathy. Catheter ablation and novel evaluation strategies was evaluated. Catheter ablation for early rhythm control of atrial fibrillation/flutter provides mortality and symptom benefits in ischemic cardiomyopathy, while scar characterization and novel ablation strategies are under investigation for ventricular tachycardia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: